Abstract
Neuropsychiatric pathologies, including neurodegenerative diseases and neurodevelopmental syndromes, are frequently associated with dysregulation of various essential cellular mechanisms, such as transcription, mitochondrial respiration and protein degradation. In these complex scenarios, it is difficult to pinpoint the specific molecular dysfunction that initiated the pathology or that led to the fatal cascade of events that ends with the death of the neuron. Among the possible original factors, epigenetic dysregulation has attracted special attention. This review focuses on two highly related epigenetic factors that are directly involved in a number of neurological disorders, the lysine acetyltransferases CREB-binding protein (CBP) and E1A-associated protein p300 (p300). We first comment on the role of chromatin acetylation and the enzymes that control it, particularly CBP and p300, in neuronal plasticity and cognition. Next, we describe the involvement of these proteins in intellectual disability and in different neurodegenerative diseases. Finally, we discuss the potential of ameliorative strategies targeting CBP/p300 for the treatment of these disorders.
Keywords: Histone acetylation, CBP, p300, Rubinstein-Taybi syndrome, Huntington’s disease, Alzheimer’s disease, HDACi, KATe, KATi.
Current Pharmaceutical Design
Title:Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders
Volume: 19 Issue: 28
Author(s): Luis M. Valor, Jose Viosca, Jose P. Lopez-Atalaya and Angel Barco
Affiliation:
Keywords: Histone acetylation, CBP, p300, Rubinstein-Taybi syndrome, Huntington’s disease, Alzheimer’s disease, HDACi, KATe, KATi.
Abstract: Neuropsychiatric pathologies, including neurodegenerative diseases and neurodevelopmental syndromes, are frequently associated with dysregulation of various essential cellular mechanisms, such as transcription, mitochondrial respiration and protein degradation. In these complex scenarios, it is difficult to pinpoint the specific molecular dysfunction that initiated the pathology or that led to the fatal cascade of events that ends with the death of the neuron. Among the possible original factors, epigenetic dysregulation has attracted special attention. This review focuses on two highly related epigenetic factors that are directly involved in a number of neurological disorders, the lysine acetyltransferases CREB-binding protein (CBP) and E1A-associated protein p300 (p300). We first comment on the role of chromatin acetylation and the enzymes that control it, particularly CBP and p300, in neuronal plasticity and cognition. Next, we describe the involvement of these proteins in intellectual disability and in different neurodegenerative diseases. Finally, we discuss the potential of ameliorative strategies targeting CBP/p300 for the treatment of these disorders.
Export Options
About this article
Cite this article as:
Valor M. Luis, Viosca Jose, Lopez-Atalaya P. Jose and Barco Angel, Lysine Acetyltransferases CBP and p300 as Therapeutic Targets in Cognitive and Neurodegenerative Disorders, Current Pharmaceutical Design 2013; 19 (28) . https://dx.doi.org/10.2174/13816128113199990382
DOI https://dx.doi.org/10.2174/13816128113199990382 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
The Nrf2-ARE Signalling Pathway: Promising Drug Target to Combat Oxidative Stress in Neurodegenerative Disorders
Current Drug Targets - CNS & Neurological Disorders Interaction of Prolyl Oligopeptidase with α-Synuclein
CNS & Neurological Disorders - Drug Targets Nitric Oxide Homeostasis in Neurodegenerative Diseases
Current Alzheimer Research Neurofilament Proteins as Prognostic Biomarkers in Neurological Disorders
Current Pharmaceutical Design Adenosine-to-Inosine RNA Editing: Perspectives and Predictions
Mini-Reviews in Medicinal Chemistry Lower Uric Acid Linked with Cognitive Dysfunction in the Elderly
CNS & Neurological Disorders - Drug Targets Patent Selections
Recent Patents on Food, Nutrition & Agriculture Pin1: A New Outlook in Alzheimers Disease
Current Alzheimer Research Multiple Defects in Energy Metabolism in Alzheimers Disease
Current Drug Targets Alzheimer's Disease: Related Targets, Synthesis of Available Drugs, Bioactive Compounds Under Development and Promising Results Obtained from Multi-target Approaches
Current Drug Targets Prevention and Treatment for Chemotherapy-Induced Peripheral Neuropathy: Therapies Based on CIPN Mechanisms
Current Neuropharmacology Mesenchymal Stromal Cells from Umbilical Cord Blood
Current Stem Cell Research & Therapy Recent Advances in the Development of Casein Kinase 1 Inhibitors
Current Medicinal Chemistry Collateral Damage: Contribution of Peripheral Inflammation to Neurodegenerative Diseases
Current Topics in Medicinal Chemistry Exploring the Role of Monoamine Oxidase Activity in Aging and Alzheimer’s Disease
Current Pharmaceutical Design Translational Challenge Models in Support of Efficacy Studies: Effect of Cerebral Hypoxia on Cognitive Performances in Rodents
CNS & Neurological Disorders - Drug Targets A Glance Over the Cannabinoid Machinery to Design New Anti- Angiogenic Compounds
Mini-Reviews in Medicinal Chemistry Parkinson’s Disease: Is there a Role for Dietary and Herbal Supplements?
CNS & Neurological Disorders - Drug Targets The Human Leukocyte Antigen Class III Haplotype Approach: New Insight in Alzheimer's Disease Inflammation Hypothesis
Current Alzheimer Research Potential Therapeutic Relevance of Adenosine A2B and A2A Receptors in the Central Nervous System
CNS & Neurological Disorders - Drug Targets